Mantle Cell Lymphoma

Patients with relapsed/refractory MCL had poor treatment outcomes with BTK inhibition, which decreased in quality as the line of therapy advanced.

Preetesh Jain, MD, MBBS, DM, PhD, discusses data from real-world analysis of treatment patterns in high-risk mantle cell lymphoma and their implications.

Fangfang Yan, MD, discusses the place of CAR T-cell therapy in the MCL treatment paradigm and how AI can address drivers of CAR T-cell therapy resistance.

Preetesh Jain, MD, MBBS, DM, PhD, discusses data with an acalabrutinib-based regimen in high-risk mantle cell lymphoma from the WINDOW-3 trial.

Andre Henri Goy, MD, discusses key developments in mantle cell lymphoma presented at the 2025 ASH Annual Meeting.

GLPG5101 produced responses and had a manageable safety profile in relapsed/refractory non-Hodgkin lymphoma, including mantle cell lymphoma.

Acalabrutinib plus rituximab followed by brexu-cel was safe and delivered responses in previously untreated, high-risk mantle cell lymphoma.

Hematology experts share the MCL abstracts they’re most looking forward to seeing at the 2025 ASH Annual Meeting.

The FDA approved a new option in resectable gastric cancer, and a new agent is under priority review in mantle cell lymphoma.

Sonrotoclax is under priority review by the FDA for the treatment of adult patients with relapsed or refractory, BTK inhibitor–pretreated MCL.

Christine Ryan, MD, discusses the limitations of current MCL treatment strategies, advances in treatment, and the evolving role of BTK inhibition.

Liso-cel was approved in the EU for relapsed/refractory MCL after at least 2 lines of therapy, including a BTK inhibitor.

Carlo Visco, MD, discusses phase 2 FIL_V-RBAC results showing venetoclax plus RBAC achieved a meaningful PFS and manageable toxicity in high-risk MCL.

Carlo Visco, MD, discussed notable ongoing MCL research and the emerging challenge of optimally sequencing therapies for the management of this disease.

A meta analysis found BTK inhibitors carry risks of hypertension, atrial fibrillation, and hemorrhage, underscoring the need for cardiovascular monitoring.

The FDA granted breakthrough therapy designation to sonrotoclax for relapsed/refractory mantle cell lymphoma.

Real-world MCL treatment with zanubrutinib generated longer treatment durations and higher treatment adherence rates vs acalabrutinib and ibrutinib.

The removal of REMS programs for approved CAR T-cell therapies could enable improved access and streamlined management of hematologic malignancies.

Ibrutinib plus rituximab showed a progression-free survival benefit vs standard chemoimmunotherapy in older patients with untreated mantle cell lymphoma.

Patients with MCL who relapsed after brexu-cel had poor survival outcomes, underscoring the need for effective post–CAR T-cell therapy strategies.

Mats Jerkeman, MD, discusses essential symptoms of MCL warranting referral for earlier diagnosis.

Ruby Arora, MD, discusses a study investigating survival outcomes and sociodemographic disparities among patients with MCL from 2000 to 2021.

BTK inhibitors were associated with lower health care resource utilization vs other regimens in mantle cell lymphoma.

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in August 2025.

A phase 1/2 trial met its primary end point of ORR with sonrotoclax in patients with relapsed/refractory MCL.